To evaluate the effect of targeting METTL3 on the in vivo efficacy of PTX and CBP, we established the xenograft tumor model by subcutaneously injecting 5 × 106 NCI-H460 cells and randomly divided mice into two batches (4 groups/batch) when the tumor volume reached 80-90 mm3. The gene discussed is METTL3; the disease is neoplasm.